• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Evolocumab successfully reduced LDL levels in pediatric patients

byConstance Wu
November 3, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Evolocumab successfully reduced low density lipoprotein (LDL) cholesterol levels in pediatric patients with heterozygous familial hypercholesterolemia.

2. Non- high density lipoprotein and apolipoprotein B levels were also improved in the evolocumab group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In the adult patient population with hyperlipidemia, human monoclonal antibodies that inhibitor PCSK9, namely evolocumab has been shown to successfully  reduce lipoprotein (LDL) cholesterol levels. However, little is known about the effects of this drug in the pediatric population. This study examined the efficacy and safety of evolocumab in children with familial hypercholesterolemia. The results were promising, revealing evolocumab effectively reduced LDL cholesterol levels when compared to the placebo. In fact, when the secondary lipid variables such as non-high density lipoprotein (HDL) and apolipoprotein B were measured, evolocumab displayed significantly better results when compared to the placebo. The study was limited by several factors. Firstly, the patient population was predominantly white. Secondly, the study was conducted for a short duration of time and therefore certain assessments could not be extrapolated upon. Similarly, long-term efficacy and safety could not be evaluated in this study. Nevertheless, this study was strengthened by its multinational population with participants form North American countries, as well as in Latin America, Asia-Pacific and European regions.

Click to read the study in NEJM

Relevant Reading: Familial hypercholesterolaemia

In-Depth [randomized controlled trial]: This study was conducted over the span of three years, between March 2016 to November 2019, across 47 sites covering a total of 23 countries over five continents.  In order for patients to be eligible for the study, a diagnosis of heterozygous familial hypercholesterolemia was required. Patients were selected if they were between 10 and 17 years of age prior to screening, with LDL cholesterol levels of 130mg per deciliter or greater and a triglyceride level of 400 mg per deciliter or less and had been on a lipid-lowering treatment for a minimum of 4 weeks. The screening period (maximum of 8 weeks) was followed by a 24-week double-blind treatment phase where the participant was randomly assigned in a 2:1 ratio to be administered one of the two treatment options, either monthly subcutaneous injections of evolocumab (420 mg) or the placebo for a total of 24 weeks. A total of 157 patients were recruited and randomized where 104 patients received evolocumab and 53 patients received a placebo. The mean age was 13.7+/-2.4 years where 85% of the participants were White among which 56% were female. The results indicated that the mean difference in the LDL cholesterol level at 24 weeks, when compared to the baseline, was -44.5% in the evolocumab group versus -6.2% in the placebo group. Overall, the study indicated that evolocumab effectively reduced LDL cholesterol levels in pediatric patients with heterozygous familial hypercholesterolemia.

RELATED REPORTS

Combination-drug therapy and earlier detection recommended to improve outcomes in heterozygous familial hypercholesterolemia

Evolocumab successfully reduced LDL levels in pediatric patients

Evolocumab plus standard therapy reduces LDL, cardiovascular events compared to standard anti-cholesterol therapy alone [OSLER-1 & OSLER-2 Trials]

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Evolocumabheterozygous familial hypercholesterolemia
Previous Post

Upadacitinib may be superior to abatecept for refractory rheumatoid arthritis

Next Post

Patients with co-occurring substance use disorder and depression less likely to receive guideline-concordant treatment

RelatedReports

2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Combination-drug therapy and earlier detection recommended to improve outcomes in heterozygous familial hypercholesterolemia

November 16, 2021
Febuxostat not effective at delaying progression of carotid atherosclerosis in asymptomatic hyperuricemia
Cardiology

Evolocumab successfully reduced LDL levels in pediatric patients

October 26, 2020
Low circulating cholesterol in neonates linked with pyloric stenosis
Cardiology

Evolocumab plus standard therapy reduces LDL, cardiovascular events compared to standard anti-cholesterol therapy alone [OSLER-1 & OSLER-2 Trials]

April 15, 2015
Low circulating cholesterol in neonates linked with pyloric stenosis
Chronic Disease

Evolocumab significantly reduces LDL cholesterol in familial hypercholesterolemia patients [TESLA-B and RUTHERFORD-2 studies]

November 30, 2014
Next Post
Parents often unaware of adolescents’ suicidal thoughts

Patients with co-occurring substance use disorder and depression less likely to receive guideline-concordant treatment

SARS-CoV-2 detected on various surroundings of asymptomatic COVID-19 positive infant

Genetic susceptibility for severe Covid-19 symptoms with respiratory failure

Lirentelimab may be effective for treatment of eosinophilic gastrointestinal disease

Lirentelimab may be effective for treatment of eosinophilic gastrointestinal disease

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.